Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Juliet, Meir"'
Publikováno v:
Expert Opinion on Drug Safety. 22:119-124
Publikováno v:
Transplantation and Cellular Therapy. 27:973-987
Chimeric antigen receptor T-cell (CAR-T) therapy has shown unprecedented response rates in patients with relapsed/refractory (R/R) hematological malignancies. While CAR-T therapy renders hope to heavily pre-treated patients, the rapid commercializati
Publikováno v:
Cardiology in Review.
Carcinoid heart disease is a frequent manifestation of carcinoid syndrome. It results from the release of a large amount of serotonin and subsequently fibrosis of right sided heart valves, that is, tricuspid and pulmonic valve. This article reviews t
Autor:
Rohan Kapur, Juliet Meir, Tauseef Ahmed, Delong Liu, Karen Seiter, Richard Sweeney, Amir Steinberg
Publikováno v:
Blood. 140:12092-12093
Publikováno v:
29th Annual Meeting North American Skull Base Society.
Autor:
Evgeny Izumchenko, Patrick K. Ha, David Sidransky, Mariana Brait, Piotr T. Wysocki, Juliet Meir
Publikováno v:
Oncotarget, vol 7, iss 40
Oncotarget
Oncotarget
Adenoid cystic carcinoma (ACC), the second most common salivary gland malignancy, is notorious for poor prognosis, which reflects the propensity of ACC to progress to clinically advanced metastatic disease. Due to high long-term mortality and lack of
Autor:
Piotr T. Wysocki, David Sidransky, Juliet Meir, Atul Bedi, Evgeny Izumchenko, Mohammad O. Hoque
Publikováno v:
Clinical Pharmacology & Therapeutics. 99:612-621
Successful drug development in oncology is grossly suboptimal, manifested by the very low percentage of new agents being developed that ultimately succeed in clinical approval. This poor success is in part due to the inability of standard cell-line x